BioSpace News Archive

Spectrum Pharmaceuticals announced that on December 5, 2022, Spectrum’s Board of Directors granted an aggregate of 736,988 inducement restricted stock units to commercial non-executive employees who were hired specifically for the launch of ROLVEDON.

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock.

Blueprint Medicines Corporation announced that, effective December 1, 2022, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 23,604 shares of its common stock and an aggregate of 11,800 restricted stock units to sixteen new employees under Blueprint Medicines’ 2020 Inducement Plan.

BioAegis Therapeutics, Inc., a clinical-stage, private company developing therapies for inflammatory diseases based on a portfolio built around gelsolin technology, announces a new article on its novel host-directed approach.

Journey Medical Corporation (“Journey Medical” or “Company”) (Nasdaq: DERM) today announced that members of Journey Medical’s management team will participate in the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022 in Miami, FL.

Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery launched the Viality lipoaspirate wash system at the Beauty Through Science meeting in NYC this past Saturday.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on January 5, 2023, to all shareholders of record as of December 16, 2022.

Solid Biosciences Inc. announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Alexander Cumbo; Chief Administrative Officer, David Tyronne Howton; Chief Scientific Officer, Friedreich’s Ataxia and Cardiac Pipeline, Jennifer Marlowe, Ph.D.; Chief Regulatory Officer, Jessie Hanrahan, Ph.D.; and Chief Technology Officer, Paul Herzich.

MEI Pharma, Inc. (Nasdaq: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced that after receiving the most recent guidance from a late November meeting with the U.S. Food and Drug Administration (FDA), the companies are discontinuing global development of zandelisib outside of Japan for B-cell malignancies.

Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at the 22nd Annual Society of Urologic Oncology Meeting demonstrating that Blue Light Cystoscopy decreases the risk and prolongs time to recurrence based on Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with Cysview® Registry database.